<unk>  is an mitotic inhibitor that is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include constipation , nausea , pyrexia , fatigue , peripheral neuropathy , febrile neutropenia , diarrhea , anemia , decreased appetite, and insomnia.
Vincristine liposome
Cytarabine liposome
Doxorubicin liposome
Daunorubicin liposome
Daunorubicin / cytarabine
Ado-trastuzumab emtansine
Liposomal daunorubicin
Vincristine sulfate